Brief: miRagen Enters Into License Agreement With Xencor For Use Of Xtend Antibody Technology For Investigational Antibodies To Treat Thyroid Eye Disease
17/12/2020 12:16
Dec 17 (Reuters) - miRagen Therapeutics Inc MGEN.O :
* MIRAGEN ENTERS INTO LICENSE AGREEMENT WITH XENCOR FOR USE
OF
XTEND™ ANTIBODY TECHNOLOGY FOR INVESTIGATIONAL ANTIBODIES TO
TREAT THYROID EYE DISEASE
* MIRAGEN THERAPEUTICS INC - EXPECTS TO FILE AN
INVESTIGATIONAL
NEW DRUG (IND) APPLICATION FOR VRDN-002, INCLUDING HALF-LIFE
EXTENSION, BY END OF 2021
Source text for Eikon: ID:nGNX8z0rN5
Further company coverage: MGEN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xencor
See all newsXencor, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments
Brief: Xencor Q2 EPS USD -0.29
Brief: Xencor To Receive $105 Million From Alexion To Resolve Ultomiris® U.S. Royalty Matter
Xencor Q1 revenue falls sharply and misses estimates